CAEL-101 for treating amyloid light chain amyloidosis

CAEL-101 is in clinical development for the treatment of amyloid light chain (AL) amyloidosis. AL amyloidosis belongs to a group of diseases called systemic amyloidosis in which deposits of proteins (called amyloids) accumulate and cause damage in tissues and organs, such as the kidneys, liver, gut, heart and nerves. In AL amyloidosis, the deposits are made up of proteins (called immunoglobulin light chains) produced in excess by malfunctioning white blood cells in the bone marrow. AL amyloidosis is a life-threatening and long-term debilitating condition because of the damage to organs, particularly the heart and kidneys. There are limited treatment options for AL amyloidosis that treats the amyloid deposits that have accumulated in tissues and organs.